Long-term efficacy of a new formulation of prostaglandin E1 as treatment for erectile failure.
OBJECTIVE
We determined the long-term efficacy of intracavernous injection of a new formulation of prostaglandin E1 (Caverject) as treatment for erectile failure.


METHODS
A prospective study was done at a university affiliated Veterans Affairs medical center. Subjects with erectile failure received injections of prostaglandin E1 at the office and self-administered injections at home for up to 18 months.


RESULTS
Of 16 patients who performed home injections 15 completed 6 months and 10 completed 18 months of therapy. Patient and spousal satisfaction with intercourse was 90% for months 1 to 6, and patient satisfaction was 95% for months 7 to 18.


CONCLUSIONS
Prostaglandin E1 was highly effective at producing penile rigidity and an erection with satisfactory vaginal intercourse.
Godschalk
M
M
Division of Geriatrics Medicine, Medical College of Virginia, McGuire Veterans Affairs Medical Center, Richmond, USA.
Gheorghiu
D
D
Chen
J
J
Katz
P G
PG
Mulligan
T
T
D000527:Alprostadil / Q000627:therapeutic use*; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D008297:Male; D011446:Prospective Studies; D013997:Time Factors; D014665:Vasodilator Agents / Q000627:therapeutic use*
D014665:Vasodilator Agents; D000527:Alprostadil